Joint aches and stiffness are among the most commonly reported symptoms of the menopause transition.

In the SWAN study of over 2,200 women, well over half reported aches and stiffness, one in six had daily symptoms, and every stage from early perimenopause through postmenopause reported significantly more aches than premenopausal women, even after adjusting for other factors. A 2024 review proposed calling this cluster, joint aches, muscle loss, bone loss and worsening osteoarthritis, the 'musculoskeletal syndrome of menopause,' reporting that more than 70% of women experience some part of it and about 25% are disabled by it. That said, a careful clinical review concludes the association is strong but that a direct, causal estrogen-deficiency link to joint pain itself remains unproven, and hormone therapy is not currently an approved or guideline-endorsed treatment for joint pain specifically.

What to know about this answer

The disagreement is whether naming this cluster a new 'syndrome' helps clinical recognition or overstates a set of loosely connected problems with very different evidence strength, since bone loss is well established while a causal link for joint pain specifically is not.

What the research shows, and which source each finding rests on

In SWAN (n=2,218), aches and stiffness were reported by well over half of midlife women, one in six had daily symptoms, and early peri-, late peri- and postmenopausal women all reported significantly more aches than premenopausal women; the postmenopause association survived full statistical adjustment.

D[1]

In 8,373 Latin American women aged 40-59, 63% had muscle and joint aches (15.6% severe); hormone therapy use was associated with lower odds of severe aches (OR 0.75), while vasomotor symptoms were the strongest correlate (OR 6.16).

C[2]

A 2024 narrative review proposed 'the musculoskeletal syndrome of menopause' as an umbrella term, reporting that more than 70% of women experience musculoskeletal symptoms through the transition and about 25% are disabled by them; these figures are synthesized from heterogeneous observational studies rather than one purpose-built cohort.

E[3]

A balanced clinical review concludes the joint-pain/menopause association is strong but that a causal estrogen-deficiency link remains unproven.

E[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

A useful new clinical entity

Vonda Wright, MD and coauthors

Naming the cluster, arthralgia, muscle loss, bone loss, osteoarthritis progression, enables recognition, risk assessment and treatment that individual, siloed complaints would otherwise miss.

E[3]

Premature syndromization

Watt, clinical review

The components have very different evidence strengths, the '>70% affected' figure aggregates heterogeneous studies, the term is a proposal rather than a recognized diagnostic entity, and a causal estrogen link to musculoskeletal pain specifically remains unproven; hormone therapy is not an approved treatment for joint pain.

E[4]

What would settle it: A prospective transition cohort with detailed musculoskeletal phenotyping, plus randomized data on estradiol for joint pain as a primary endpoint, neither of which currently exists.

What is really going on here

  1. Is this documented in studies, reported by clinicians, or just circulating online?
  2. '80% of women get the musculoskeletal syndrome' versus the paper's own '>70%' figure - which number should I trust?

Questions for your doctor

  1. Could my joint pain be connected to perimenopause, and what would rule that in or out?
  2. Is hormone therapy an appropriate option for joint pain specifically, or only for other symptoms?
  3. Should we check for other causes, like autoimmune or thyroid conditions?
  4. What non-hormonal approaches, like strength training, might help?

Questions with no answer yet

Would a randomized trial of estradiol specifically for joint pain, using joint pain as the primary outcome rather than a secondary observation, find a real effect, or would it come back null the way the direct hormone therapy test for frozen shoulder did?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Randomized data on estradiol for arthralgia as a primary endpoint does not currently exist, and a balanced clinical review concludes the association between menopause and joint pain is strong but a causal estrogen-deficiency link remains unproven.

What would test it: A randomized trial of estradiol specifically powered and designed with joint pain as its primary outcome.

Does naming this cluster of symptoms a single syndrome actually change clinical recognition and treatment for the better, or does grouping together conditions with very different evidence strength, well-established bone loss alongside unproven joint-pain causation, risk overselling how connected they really are?

Partly studied

What is known: Naming the cluster is argued to enable recognition, risk assessment, and treatment, while the counter-position notes the components have very different evidence strengths and that the term is a proposal, not a recognized diagnostic entity. A prospective transition cohort with detailed musculoskeletal phenotyping, explicitly called for by the term's own proponent, would help settle this.

What would test it: The prospective, phenotyped transition cohort described above.

Since musculoskeletal pain was found in one large study to be strongly correlated with vasomotor symptoms specifically, would treating hot flashes and night sweats meaningfully reduce joint pain as a side effect, or are the two symptoms simply co-occurring rather than causally linked?

Partly studied

What is known: In one Latin American cohort, vasomotor symptoms were the strongest correlate of severe joint aches, far stronger than hormone therapy use itself, but no trial has tested whether treating vasomotor symptoms specifically, independent of any direct hormone effect on joints, reduces joint pain as a measured outcome.

What would test it: A trial isolating vasomotor symptom treatment, for example a nonhormonal option, with joint pain as a pre-specified secondary outcome, to see whether relief of one symptom reduces the other.

Sources

  1. 1.Musculoskeletal pain and menopausal status.Dugan SA, et al. Musculoskeletal pain and menopausal status. Clin J Pain 2006;22(4):325-31 · Comparative or small study
  2. 2.Menopause could be involved in the pathogenesis of muscle and joint aches in mid-aged women.Blumel JE, et al. Menopause could be involved in the pathogenesis of muscle and joint aches in mid-aged women. Maturitas 2013;75(1):94-100 · Observational study
  3. 3.The musculoskeletal syndrome of menopause.Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric 2024;27(5):466-472 · Review, opinion or mechanism
  4. 4.Musculoskeletal pain and menopause.Watt FE. Musculoskeletal pain and menopause. Post Reprod Health 2018;24(1):34-43 · Review, opinion or mechanism

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides